Elinzanetant, a dual NK1R/NK3R antagonist, appears to offer even greater symptom relief, as reported by the recently published OASIS-4 trial evaluating the efficacy and safety of this molecule in a specific population of patients with ER+ BC undergoing endocrine therapy [57]. The gene discussed is TACR1; the disease is breast cancer.